Cargando…

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

Alterations in the innate and adaptive immunity underpin psoriasis pathophysiology, with the Th17 cells subset now recognized as the fundamental cells in the key controlling pathway involved in its pathogenesis. Since psoriasis is a systemic disease with important comorbidity, further knowledge on t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egeberg, A., Gisondi, P., Carrascosa, J.M., Warren, R.B., Mrowietz, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496750/ https://www.ncbi.nlm.nih.gov/pubmed/32022950 http://dx.doi.org/10.1111/jdv.16273

Ejemplares similares

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
por: Menter, Alan, et al.
Publicado: (2021)

A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
por: Armstrong, April W., et al.
Publicado: (2022)

Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment
por: Prinz, Immo, et al.
Publicado: (2019)

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
por: Puig, Lluís
Publicado: (2017)

The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
por: Schön, Michael P., et al.
Publicado: (2018)

Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)
por: Cauli, Alberto, et al.
Publicado: (2015)

Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis
por: Wang, Yan, et al.
Publicado: (2022)

Interleukin-23 and Th17 Cells in the Control of Gut Inflammation
por: Monteleone, Ivan, et al.
Publicado: (2009)

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015)

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
por: Avallone, Gianluca, et al.
Publicado: (2023)

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
por: Warren, R.B., et al.
Publicado: (2019)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Interleukin-17A and Keratinocytes in Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2020)

Evaluation of the Th17 pathway in psoriasis and geographic tongue()()
por: Picciani, Bruna Lavinas Sayed, et al.
Publicado: (2019)

Interleukin-17A and interleukin-23 in morphea
por: Dańczak-Pazdrowska, Aleksandra, et al.
Publicado: (2012)

Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
por: Cai, Jiangluyi, et al.
Publicado: (2021)

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2020)

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study
por: Petersen, Magnus B, et al.
Publicado: (2023)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
por: Quatresooz, Pascale, et al.
Publicado: (2012)

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study
por: Cortese, Andrea, et al.
Publicado: (2023)

Interleukin-17 and - 23 Inhibitors Associated with Direct Effects on Depressive Symptoms in Psoriasis: A Register Study
por: SVEDBOM, Axel, et al.
Publicado: (2023)

Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis
por: Kaur, Rajinder, et al.
Publicado: (2018)

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
por: Sawyer, Laura M., et al.
Publicado: (2019)

Psoriasis and Myasthenia Gravis: A Common Th-17 Pathway
por: El Sayed, Fouad, et al.
Publicado: (2022)

Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials
por: Mosca, Megan, et al.
Publicado: (2021)

From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
por: Vidal, Silvia, et al.
Publicado: (2021)

Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis
por: Wang, Runsheng, et al.
Publicado: (2021)

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
por: Thatiparthi, Akshitha, et al.
Publicado: (2021)

Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis
por: Elghandour, Tarek Mahmoud, et al.
Publicado: (2013)

The potential role of Th17 lymphocytes in patients with psoriasis
por: Mansouri, Mahnaz, et al.
Publicado: (2018)

Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
por: Valenzuela, Fernando, et al.
Publicado: (2022)

The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis
por: Girolomoni, G., et al.
Publicado: (2017)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Inhibition of interleukin‐12 and/or interleukin‐23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
por: Ergen, Elizabeth N., et al.
Publicado: (2018)

Interleukins 17 and 23 in patients with gastric neoplasms
por: Błogowski, Wojciech, et al.
Publicado: (2016)

Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways
por: Piaserico, Stefano, et al.
Publicado: (2022)

The Role of IL-23/Th17 Pathway in Patients with Primary Immune Thrombocytopenia
por: Ye, Xin, et al.
Publicado: (2015)

Th17 and Th22 cells in psoriatic arthritis and psoriasis
por: Benham, Helen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8otf0rn3e4b271nvbk8eu06v40